INTRODUCTION {#s1}
============

Gastric cancer remains one of the leading causes of cancer-related death worldwide, with approximately 950,000 new diagnoses each year and 720,000 deaths in 2012 \[[@R1]\]. The optimal therapeutic option for patients with resectable gastric cancer is surgical intervention. Adjuvant therapies were given mainly to improve postoperative survival in patients who have received R0 resection of locally advanced gastric cancer, with an estimated increase of 5-year overall survival (OS) by 10--15% \[[@R2]\]. However, no consensus about the optimal treatment strategy has been reached. It has been shown that patients with gastric cancer receiving postoperative fluoropyrimidine-based and platinum-based chemotherapy gain survival benefits \[[@R3], [@R4]\]. In recent years, several clinical trials have found a potential advantage of adjuvant chemoradiation over chemotherapy \[[@R5]--[@R7]\]. The US 0116 trial found that compared with surgery, chemoradiotherapy could significantly reduce mortality and risk of tumor recurrence \[[@R8], [@R9]\]. However, the ARTIST trial conducted in South Korea showed that for patients with gastric cancer who underwent D2 lymph-node dissection, chemoradiotherapy to chemotherapy did not add survival benefits in terms of disease-free survival (DFS) or OS \[[@R10]\]. Therefore, the prognostic effects of adjuvant chemoradiotherapy for patients with gastric cancer remain uncertain. We therefore performed an updated meta-analysis to reassess the prognostic value for chemoradiotherapy for gastric cancer patients receiving surgery.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

We identified 1099 records from the database search and seven additional records from other sources (Figure [1](#F1){ref-type="fig"}). After title or abstract screening, 174 relevant records met our inclusion criteria, and their full texts were assessed. Of these, 15 RCTs contained at least one common outcome with sufficient data \[[@R3]--[@R7], [@R11]--[@R20]\], leaving 10 and six eligible trials for 5-year OS and DFS/recurrence-free survival (RFS) analysis, respectively. The trials were published between 1979 to 2015 as full articles. There were 1575 patients in the experiment arm (chemoradiotherapy group) and 1541 patients in the control arm (chemotherapy group), with a range of sample size from 61 to 559. Three trials were performed in USA \[[@R6], [@R15], [@R16]\], five in Europe \[[@R11], [@R13], [@R17]--[@R19]\], six in Asia \[[@R3]--[@R5], [@R7], [@R14], [@R20]\] and one in Africa \[[@R12]\]. The median follow-up ranged from 24 to 128 months. Almost all the patients from the included trials received surgery. The total dose of radiotherapy was 45Gy in 8 of the 15 trials and 20Gy in 4 trials. Ten trials reported 5-year OS and 6 reported 5-year DFS or RFS (Table [1](#T1){ref-type="table"}). The methodological quality of each trial eligible for this meta-analysis is summarized in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

![Flow chart for the process of identifying trials included in and excluded from the systematic review](oncotarget-08-102880-g001){#F1}

###### Major features of the included randomized controlled trials

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author   Publication year   Country        Inclusion period   Mean/median age(years): (Exp. versus Control)   Tumor stage   Median follow up period (months)   Total sample size   No.CRT   No.CT   Lymphadenectomy   Mean/median No. of dissected LNs(Exp. versus Control)   Treatment regimen   Total RT dose (Gy)   Primary endpoints
  -------------- ------------------ -------------- ------------------ ----------------------------------------------- ------------- ---------------------------------- ------------------- -------- ------- ----------------- ------------------------------------------------------- ------------------- -------------------- -------------------------
  Yu             2012               China          2006--2007         56 versus 57                                    II            36                                 68                  34       34      D1,D2             NR                                                      S+CRT/S+CT          45                   3-year OS; 3-year DFS

  Smalley        2012               USA            1991--1998         NR                                              I-IV          123.6                              559                 282      277     D0,D1,D2          NR                                                      S+CRT/S             45                   10-year OS; 10-year RFS

  Kim            2012               Korea          2002--2006         ≤ 60 (80.4) versus\                             III-IV        86.7 (60.3--116.5)                 90                  46       44      D2                46.5 (21--93) versus\                                   S+CRT/S+CT          45                   10-year OS;10-year RFS
                                                                      ≤ 60 (68.2)                                                                                                                                             41 (22--129)                                                                                     

  Zhu            2012               China          2003--2008         56 (38--73) versus 59 (42--75)                  I-IV          42.5                               351                 186      165     D2                NR                                                      S+CRT/S+CT          45                   5-year OS; 5-year DFS

  Bamias         2010               Greece         2002--2005         63 (32--75) versus\                             I-IV          53.7 (0.1--77.8)                   143                 72       71      D0,D1,D2          14 (3--76) versus\                                      S+CRT/S+CT          45                   3-year DFS
                                                                      62 (41--79)                                                                                                                                             14 (0--62)                                                                                       

  Kwon           2010               Korea          2002--2004         56 (23--73) versus\                             III-IV        77.2 (24--92.8)                    61                  31       30      D2                NR                                                      S+CRT/S+CT          45                   5-year OS; 5-year DFS
                                                                      49 (29--70)                                                                                                                                                                                                                                              

  Stahl          2009               Germany        2000--2005         56.0 versus 60.6                                I-IV          45.6                               126                 62       64      D2                22 (5--61) versus\                                      S+CRT/S+CT          30                   3-year os
                                                                                                                                                                                                                              16 (7--38)                                                                                       

  Moertel        1984               USA            1965--1974         58 (40--72) versus 56 (41--67)                  NR            NR                                 62                  39       25      NR                NR                                                      S+CRT/S             37.5                 5-year OS; 5-year RFS

  Hallissey      1994               UK             1981--1986         65 (55--69) versus 63 (57--69)                  II-IV         84                                 436                 153      145     D1                NR                                                      S+RT/S              45                   5-year OS

  Zhang          1998               China          1978--1989         55.8 (39--66)\                                  I-IV          128 (89--192)                      370                 171      199     NR                NR                                                      S+RT/S              40                   5-year OS;10-year OS
                                                                      versus 56.1 (32--65)                                                                                                                                                                                                                                     

  Skoropard      2002               Russia         1974--1978         55 (25--75) versus 54 (36--71)                  I-IV          240                                152                 77       75      D1                NR                                                      S+RT/S              20                   5-year OS;10-year OS

  Skoropard      2000               Russia         1993--1998         54 (27--79) versus 55 (28--74)                  NR            72                                 112                 59       53      D1                NR                                                      Pre RT& IORT/S      20                   5-year OS; 5-year RFS

  Shchepotin     1994               USA            1984--1986         55 (26--76)                                     II-IV         NR                                 293                 98       100     NR                NR                                                      S+RT/S              20                   3-year OS

  Dent           1979               South Africa   1974--1976         NR                                              NR            NR                                 66                  35       31      NR                NR                                                      S+CRT/S             20                   3-year OS;5-year OS

  Park           2015               Korea          2004--2008         56 (28--76) versus\                             I-IV          84                                 458                 230      228     D2                40 (12--84) versus\                                     S+CRT/S+CT          45                   5-year OS; 5-year DFS
                                                                      56 (22--77)                                                                                                                                             40 (13--142)                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CRT = chemoradiotherapy; CT = chemotherapy; DFS = disease-free survival; LNs = lymph nodes; NR = not report; OS = overall survival; RFS = recurrence-free survival; RT = radiotherapy; S = surgery.

Primary endpoint: 5-year OS {#s2_2}
---------------------------

Ten included trials provided 5-year OS data, and the relative risk (RR) and 95% CI for each study as well as the pooled RR are presented in Figure [2](#F2){ref-type="fig"}. The overall summary estimated RR for 5-year OS was 1. 05 (95% CI: 0.88 to 1.25). Moderate heterogeneity was revealed that *I*^2^ was 55.7% and the *P* for heterogeneity was 0.016, using a random-effect model. We also conducted subgroup analyses stratified by inclusion period, trial region, sample size, treatment regimen, total radiotherapy dose and patient follow-up period and the results indicated that some of the heterogeneity of most of the subgroups decreased significantly, but the summary estimates remained constant with no 5-year OS benefits.

![Summary estimates and 95% CIs for 5-year overall survival comparing chemotherapy alone with combined chemoradiotherapy in patients with gastric cancer\
Weights are from random effects analysis. Abbreviations: CI, confidence interval; RR, relative risk; W (random): Weights (random effects model).](oncotarget-08-102880-g002){#F2}

Secondary endpoint: 5-year DFS/RFS {#s2_3}
----------------------------------

Six trials provided 5-year DFS/RFS data and the RR and 95% CI for each study and the overall summary estimated RR was 0.89 (95% CI: 0.81 to 0.98). No heterogeneity was tested that *I*^2^ = 0% and the *P* for heterogeneity was 0.44, using a fixed-effect model.

Publication bias and sensitivity analyses {#s2_4}
-----------------------------------------

For 5-year OS, the funnel plot (Figure [3](#F3){ref-type="fig"}) shows little evidence of asymmetry, and the results from both the Begg's test (*P* = 0.929) and the Egger's test (*P* = 0.247) also indicated no evidence of publication bias. Sensitivity analyses by using the trim and fill method and the ''one study removed'' procedure, the adjusted results remained unchanged. We did not test pulication bias for 5-year DFS/RFS due to limited included trials.

![Symmetric funnel plot of trials included in meta-analysis suggesting no evidence of publication bias](oncotarget-08-102880-g003){#F3}

DISCUSSION {#s3}
==========

This meta-analysis, based on 15 RCTs, compared survival outcomes with chemoradiotherapy versus chemotherapy alone for patients with gastric cancer receiving surgery. The findings revealed no evidence of an increased 5-year OS benefit for chemoradiotherapy compared with chemotherapy alone. However, chemoradiotherapy could provide a 5-year DFS/RFS benefit.

Several previous meta-analyses have investigated the effect of adjuvant radiotherapy for gastric cancer \[[@R21]--[@R25]\]. Though most of the meta-analyses yielded survival advantage of radiotherapy, some other trials did not find significant survival advantage of chemoradiotherapy over chemotherapy \[[@R11], [@R12], [@R14], [@R15], [@R17], [@R19]\]. Ours is the first one on this topic to specially address long-term survival benefits in terms of 5-year OS and DFS or RFS. The findings of our report are partly similar to five previous published meta-analyses. Dai *et al* reported that the use of chemoradiotherapy was associated with a 50% increase in 5-year DFS \[[@R25]\]. Others also found consistent results for postoperative radiotherapy \[[@R21], [@R22]\]. However, we did not find significant survival benefit for chemoradiotherapy in terms of 5-year OS.

5-year OS is the most frequently recorded long-term outcome in the clinical studies for gastric cancer and the most accurately measure after treatment. Although the difference between chemoradiotherapy and chemotherapy alone did not reach statistical significance for all the included trials (RR 1.05 95% CI 0.88 to 1.25), the trend toward an improved 5-year DFS/RFS was observed for the treatment of chemoradiotherapy over single chemotherapy (RR 0.89 95% CI 0.81 to 0.98). Updating the pooled results from the current included trials in a meta-analysis increases statistical power and may provide sufficient evidence to reassess the survival effect of chemoradiotherapy more reliably. The included trias were then stratified into several subgroups according to baseline features, and consistently, almost all the subgroup analyses showed that there was no statistical significant difference between chemoradiotherapy and single chemotherapy for 5-year OS (Table [2](#T2){ref-type="table"}).

###### Subgroup analyses based on some baseline characteristics of included randomized controlled trial for 5-year overall survival

                              Hazard ratio   95% Confidence interval   Degree of heterogeneity (*I*^2^ statistics; %)   *P*-value   *P*^\*^-value   No. of included Studies
  --------------------------- -------------- ------------------------- ------------------------------------------------ ----------- --------------- -------------------------
  **Inclusion period**                                                                                                                              
   **Before year 2000**       1.21           0.83 to 1.76              64.9                                             0.023       0.012           5
   **After year 2000**        0.94           0.85 to 1.03              0                                                0.630       5               
  **Study region**                                                                                                                                  
   **USA**                    1.90           0.72 to 4.96              32.5                                             0.224       0.038           2
   **Europe**                 0.98           0.61 to 1.55              61.4                                             0.075       3               
   **Asia/Africa**            0.98           0.83 to 1.15              43.4                                             0.132       5               
  **Sample size**                                                                                                                                   
   **\<300**                  1.19           0.91 to 1.55              28.1                                             0.224       0.047           6
   **≥300**                   0.96           0.77 to 1.19              68.1                                             0.024       4               
  **Treatment regimen**                                                                                                                             
   **S+CRT/S+CT**             1.05           0.88 to 1.02              0                                                0.82        0.007           4
   **S+CRT/S**                5.31           0.72 to 39.24             −                                                −           1               
   **S+RT/S**                 1.19           0.88 to 1.61              57.5                                             0.051       5               
  **Total RT dose (Gy)**                                                                                                                            
   **20 Gy**                  1.33           1.04 to 1.71              0.0                                              0.646       0.001           3
   **45 Gy**                  0.91           0.83 to 1.00              0.0                                              0.473       5               
   **others**                 1.89           0.71 to 5.03              33.8                                             0.219       2               
  **Follow-up period (ms)**                                                                                                                         
   **\<60**                   0.89           0.73 to 1.07              −                                                −           0.026           1
   **≥60**                    1.01           0.82 to 1.25              47.8                                             0.074       7               

Abbreviations: CRT = chemoradiotherapy; CT = chemotherapy; ms = months; RT = radiotherapy; S = surgery.

Note: *P*^\*^ indicated the difference of between- subgroup heterogeneity

Although there are subtle differences between the measurement of PFS and RFS in terms of definition, we summarised these two outcome measures together in that few articles reporting these two outcomes while have more similarities. While this meta-analysis indicated that chemoradiotherapy benefit more than chemotherapy alone for DFS/RFS, we could not draw a solid conclusion as the small statistical power. More large-scale high-quality RCTs will add the evidence to confirm this association.

Several major limitations have to be addressed in this meta-analysis. Firstly, the design of the included trials varied to the different extent in the meta-analysis. For instance, the dose of radiotherapy ranged from 20--45 Gy with different timing which were not thoroughly investigated due to insufficient data from original reports. Secondly, for the nature of study level meta-analysis, we could not fully adjust some prognostic influential factors, such as tumor stage, patient age, molecular and pathological features, which could not allow us to perform related subgroup analyses. We need further well designed clinical trials to explore the best available evidence on the subject. Thirdly, other relatively short-term outcomes or adverse events are not assessed. Therefore, more multicenter well designed clinical trials are needed to further clarify the real prognostic role in specific patient profiles for gastric cancer.

There are several strengths for our meta-analysis. Firstly, thoroughly database search was conducted without language or publication date limits, to a great extent minimising the risk of missing trials. Secondly, we included the largest sample size of more than 3300 patients and conducted the most comprehensive meta-analysis regarding chemoradiotherapy and 5-year OS for gastric cancer, providing the most reliable evidence for this subject to date. Thirdly, stratified analyses have been performed based on some of the major trial features, such as study design and patient characteristics, treatment regimen and follow-up period, and the results were generally consistent and reliable. Fourthly, literature search, selection and bias assessent were done with cross-check style by two authors independently and reassessed by a senior author, guarantee the process of systematic review more objectively.

In summary, this updated meta-analysis does not provide strong evidence for a 5-year survival benefit of chemoradiotherapy over chemotherapy alone in patients with gastric cancer. A clear advantage of chemoradiotherapy over chemotherapy has not been established. Further larger RCTs should be conducted to determine its true effect. We suggest that future RCTs should be well designed for more consistent patient selection criteria, such as the consistent surgical approach and adjuvant strategy of gastric cancer, similar patient features including lymph node status and tumor histology.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We conducted a systematic literature search of three databases including PubMed, Embase and the Cochrane Library from inception through April 2017 for all randomized controlled trials investigating the prognostic effect of combined chemoradiotherapy for patients with gastric cancer compared with that of single chemotherapy. We presented the detailed search strategies of the three databases in [Supplementary materials](#SD1){ref-type="supplementary-material"}. In summary, the following MeSH/EMTREE terms jointed with free-text words are utilized: "gastric/stomach", "cancer\*/tumo?r\*/carcinom\*/neoplas\*/adenocarcinoma\* /malignan\*", "radiotherap\* OR radio-therap\*", and "randomized controlled trial/ controlled clinical trial/randomi?ed/placebo/randomly". We also tracked the citations of the included trials and reviews identified during the selection process for additional relevant publications. Unpublished grey literature was not searched for limited data available. The searching date or language was not restricted.

Study selection and inclusion criteria {#s4_2}
--------------------------------------

Two investigators (MW and CL) assessed trial inclusion eligibility independently through reading the titles or abstracts identified through database search. If the citations were evaluated to be relevant, then they would be retrieved for full text reviews. Any disagreements were resolved by consensus or by a senior investigator (CW) if necessary.

Randomized controlled trials were selected eligible for inclusion if they met the following criteria: (1) randomized in trial design; (2) enrolled adults who were clinically and pathologically diagnosed gastric cancer; (3) presented prognostic data for gastric cancer patients treated with adjuvant (chemo)radiotherapy and/or sugery compared with those with single adjuvant chemotherapy and/or sugery; (4) survival estimates such as OS, DFS or RFS were given. We excluded non-RCTs, reviews, editorials, letters, and trials with no relevant outcomes or sufficient data for analysis. OS was defined as the time from randomisation to death from any cause, and DFS or RFS was defined as the time from randomisation to first reappearance of gastric cancer or death from any cause. We applied 5-year survival statistics in that it is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as gastric cancer.

Data abstraction {#s4_3}
----------------

Data from the included trials were abstracted using a predefined data abstraction form for each trial containing the following baseline characteristics: the first author name, publication year, trial country, inclusion period, patient mean/median age, tumor stage, median follow up period, total sample size, type of lymphadenectomy, mean/median number of dissected lymph nodes, treatment regimen, total RT dose (Gy) and primary endpoints.

Assessment of methodological quality {#s4_4}
------------------------------------

Two independent investigators assessed the methodological quality of each trial included in the present meta-analysis using the tool recommended by the Cochrane Handbook for Systematic Reviews of Interventions for RCTs \[[@R26]\]. Seven domains were assessed, namely, random sequence generation; allocation concealment; blinding of participants, personnel, blinding of outcome assessment; completeness of outcome data; freedom from selective reporting; and freedom from other bias.

Statistical analysis {#s4_5}
--------------------

The statistical data analysis was performed using Stata^®^ version 12.0 (StataCorp LP, College Station, Texas, USA). The presence of heterogeneity among trials was assessed by using Cochrane's ^χ2^ test, defining a *p* value less than 0.10 as evidence of heterogeneity. The extent of heterogeneity was assessed using *I*^2^ statistic, with an *I*^2^ more than 50% indicating substantial heterogeneity \[[@R27]\]. We used the random-effect model to combine the effect estimates and subgroup analyses were also applied to further investigate the sources of heterogeneity. We proposed the following study characteristics for heterogeneity including inclusion period, trial region, sample size, treatment regimen, total radiotherapy dose and patient follow-up period. Summary estimates with 95% CIs were obtained for each outcome measure (OS or DFS/PFS). Publication bias was also tested by inspection funnel plot asymmetry and with Begg's rank correlation test and Egger's linear regression test, with a *P* value less than 0.05 as an indication of publication bias \[[@R28], [@R29]\]. Sensitivity analysis using the Duval and Tweedie "trim-and-fill" method has also been conducted to further confirm the robustness of the main analyses \[[@R30]\].

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================

**CONFLICTS OF INTEREST**

The authors declare no competing financial interests.

**GRANT SUPPORT**

None.

[^1]: These authors contributed equally to this work
